BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checkli st.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
provide more feedback here or in Methods on development of CoMiSS.
-Clinical setting and study population. It's unclear why the study is being conducted in China and whether the tool is culturally appropriate. In particular, the tool was developed by Europeans, written in English, and possibly contains inappropriate references (e.g. "a coffee spoon.") I think the protocol should address this challenge and whether the tool will be translated for full understanding by all investigators, clinicians, and participants. Additionally, please elaborate on exclusively formula fed and why exclusion of infants fed formula plus breast milk or other liquids/solids need to be excluded and how that decision may affect selection bias.
-Inclusion and exclusion criteria. I sample selection figure would be more clear and ineligible vs. excluded participants should be delineated. Also please explain why preterm and LBW infants are ineligible and which medical conditions are reason for exclusion (e.g. other allergies or autoimmune disorders?) -Interventions. Please define "open oral food challenge" and explain why it is being used and an appropriate alternative to a placebocontrolled food challenge. This is particularly important for replication purposes. Please describe what measures will be in place to assess adherence. Study dates need to be provided per journal instructions.
-Statistical analysis. Hypothesis is one-sided but statistical significance used is two-sided. It would helpful to site a basis for choosing an AUC of 0.75. Please also calculate PPV and PNV in addition to Sensitivity and Specificity. Please detail what is meant by 'different logistic regression models' will be tested. Formulas look like they were copy and pasted, but should be written in the document. Also in multiple places the digit is missing in the formula and shown as a dotted box. Please give a reason for doing a 1:1 training:holdout set as a smaller holdout set or use of resampling cross-validation would reduce the sample size and thus subject burden.
Southampton UK REVIEW RETURNED 21-Nov-2017 GENERAL COMMENTS This is a well designed large study to determine the ability of the COMiSS tool to be used for diagnostic purposes for CMPA, thereby potentially saving the need for oral food challenges.The study is well designed. I am unable to comment on the statistical components which should be reviewed by a qualified statistician.
I have a few comments / requests for clarification / justification. Patients should be consecutively included with no regard to the severity of the disease in order to avoid a biased study. The study should enroll prospectively all consecutive eligible patients with suspected disease. For example studies that make inappropriate exclusions, (excluding "difficult to diagnose" patients), may result in overoptimistic estimates of diagnostic accuracy. Therefore study subjects recruitment methods should be better specified.
3.
The ability of the index test to indicate which individuals have milk allergy and which do not can change with the prevalence of disease. For this reason it is important to know the population for which CoMISS is intended to be used (general or tertiary center population). In line 37 page 5 you write that the primary goal is the development of a diagnostic tool for CMPA intended for use in the primary care setting and in line 18 page 9 you write that the recruitment of the study subjects will take place in 10 pediatric departments; further information on level of care setting is required.
4.
The OFC results will be interpreted without knowledge of the results of the CoMISS (line 12 page 8) however the interpretation of index test results may be influenced at the third visit by knowledge of the OFC results. It would be better if both investigators are blinded. 5.
In the "study objectives" section you write that the main aim of the trial is to validate the CoMiSS against the diagnostic reference standard, the OFC. In the introduction of abstract and in other sections (line 14 page 5, line 38 page 12), you also write that the aim of the study is to validate the CoMiSS as a potential diagnostic tool for CMPA and as a predictor of CMPA. I think you run the risk of failing to answer the main aim it set out to achieve. Your purpose is actually to propose the CoMISS as a diagnostic test for milk allergy and not as a screening test. CoMISS cut-off should minimize false positives because the purpose of CoMISS is to avoid OFC for those patients suspected to be allergic and to avoid useless elimination diets. In line 7 page 13 you write "a meaningful CoMiSS cut-off can be identified that would provide a high sensitivity (around 80%-90%) and moderate specificity in the range of 60%-70%" however for the mentioned reasons you should identify CoMiss cut-off that would provide a high specificity. 6.
The determination of CoMISS optimal cut-off is among the secondary objectiveness. Cut-off based on the best combination between sensibility and specificity does not allow to adequately select patients at high risk of reacting to the OFC. Furthermore sensibility and specificity are a fixed characteristic of the test. In order to obtain most clinically useful measures, I suggest you to provide Likelihood Ratio (LR). LR is one of the most clinically useful measures, more useful than sensitivity or specificity and summarize information about a diagnostic test by combining sensitivity and specificity. 7.
In abstract section you indicate that the study will calculated the difference between CoMISS 1 and 2 but this aim is not listed in the outcomes section. 8.
Enrolment is indicated in figure 2 at visit 1 while you write in the manuscript that infants will be considered for inclusion at visit 2 (line 28 and 47 page 24).
Best wishes,
VERSION 1 -AUTHOR RESPONSE

Editorial Requests
Please revise your title so that it includes your study design. This is the preferred format for the journal. The study title has been amended to reflect the study design.
Please include the date that you expect to complete data collection. Data collection will be completed by June 2018. This has been added to the manuscript. Please shorten the 'Strengths and Limitations' section on page 5. This section should contain up to five short bullet points, no longer than one sentence each, that relate specifically to the methods of the study reported. Five short bullet points have been provided. Along with your revised manuscript, please provide a completed copy of the SPIRIT checklist (http://www.spirit-statement.org/). Please remember to include the relevant page number(s) from the manuscript next to each reporting item or state 'n/a' next to items that are not applicable to your study. For help and guidance completing the checklist see: http://www.bmj.com/content/346/ bmj.e7586 The SPIRIT checklist has been provided. Reviewer: 1 Limitations of the study should be better presented. In particular it should be stated that several common CMA-induced symptoms are not included in the "symptom score" provided by the Authors , such as vomiting, macroscopic blood in the stool, failure to thrive, etc. A short list of 5 bullet points of study limitations has been provided. An added sentence in the introduction acknowledges the CoMiSS does not included a comprehensive list of symptoms of cow's milk protein allergy, e.g. vomiting, rectal bleeding or failure to thrive. However, it is a published and widely used clinical awareness tool. Reviewer: 2 Strengths and Limitations section. Please group strengths and limitations separately instead of alternating them in a list. I also think more is needed to defend the limitation of using a single-blind open food challenge as the validation standard. "Less resource-consuming and in line with real world clinical practice" does not defend its use as a gold standard to validate against. Please refer to comments made above. The open food challenge has been discussed in the limitations of the study. According to the ESPGHAN guidelines for CMPA, an open food challenge is described as an acceptable clinical practice (refer to reference #3). Introduction. Add more background for the study objectives besides tool validation. In particular, the causes of CMPA as the study will be assessing risk factors for the condition. Also please provide more feedback here or in Methods on development of CoMiSS. Validation of the CoMiSS tool is the main objective of the study. We feel that the discussion of the causes of CMPA is beyond the scope of this protocol manuscript. The rationale for the CoMiSS has been described briefly. A more detailed summary of the rationale behind the tool is provided in reference #5. Clinical setting and study population. It's unclear why the study is being conducted in China and whether the tool is culturally appropriate. In particular, the tool was developed by Europeans, written in English, and possibly contains inappropriate references (e.g. "a coffee spoon.") I think the protocol should address this challenge and whether the tool will be translated for full understanding by all investigators, clinicians, and participants. Additionally, please elaborate on exclusively formula fed and why exclusion of infants fed formula plus breast milk or other liquids/solids need to be excluded and how that decision may affect selection bias. The CoMiSS tool was developed as a global clinical awareness tool. As cow's milk allergy is prevalent in China, we chose this country to safeguard timely recruitment. The tool was reviewed and translated by the Chinese investigators of this study. The protocol was also reviewed and approved by the local ethics committee, and no cultural concerns were raised.
Inclusion and exclusion criteria. I sample selection figure would be more clear and ineligible vs. excluded participants should be delineated. Also please explain why preterm and LBW infants are ineligible and which medical conditions are reason for exclusion (e.g. other allergies or autoimmune disorders?)
We felt that premature infants and LBW infants would represent a separate group from otherwise healthy term infants, due to different growth trajectories and possible other comorbidities. In order to reduce heterogeneity in the study population, it was therefore decided to exclude preterm and LBW infants from the study. Interventions. Please define "open oral food challenge" and explain why it is being used and an appropriate alternative to a placebo-controlled food challenge. This is particularly important for replication purposes. Please describe what measures will be in place to assess adherence. Study dates need to be provided per journal instructions.
See above comments. The challenge procedure is described in a dedicated paragraph in the manuscript. Adherence to the challenge procedure is monitored by study nurses and doctors by parent interview at each visit. Study dates have been added, as requested.
Statistical analysis. Hypothesis is one-sided but statistical significance used is two-sided.
While the overall significance level for the study is set at 0.05, a significance level of 0.025 will be applied for one-sided hypothesis tests. 95% two-sided confidence intervals.will be obtained accordingly. It would helpful to site a basis for choosing an AUC of 0.75. This corresponds with a one-point ROC curve with 90% sensitivity and 60% specificity. Please also calculate PPV and PNV in addition to Sensitivity and Specificity. This has been added to the manuscript. Likelihood ratios will also be calculated. Please detail what is meant by 'different logistic regression models' will be tested. In the training set, different covariates may be adjusted for to choose the best model that (i) achieves high predictive accuracy (tested using cross-validation) and (ii) has the best goodness-of-fit. Formulas look like they were copy and pasted, but should be written in the document. Also in multiple places the digit is missing in the formula and shown as a dotted box. We would like to confirm with the editorial office what the preferred format for mathematical equations is.
Please give a reason for doing a 1:1 training:holdout set as a smaller holdout set or use of resampling cross-validation would reduce the sample size and thus subject burden. The validation dataset size is powered and the training set needs to be at least a big as the validation set. Cross-validations are performed within the training set to determine the best model as well as the optimal threshold on the ROC curve. Unbiased estimates for sensitivity, spec ificity, PPV, NPV, LR+ and LR-will be obtained using the validation dataset only. Reviewer: 3 The manuscript is, in my opinion, theoretical.
-No data on infants' symptoms are reported by authors. -Which kind of Non IgE mediated food allergy the infants had? Please see and report international classification. of both EAACI and AAAAI. -Someone had a sponteneous improvement CM allergy ? -Please report in detail the symptoms that occurred during OFC for either each patients or group of patients . In addition, as I am clinician I have n. 2 questions 1-Where is the discussion of the manuscript? 2-Why n. 4 pages of statistical analysis ?
This a protocol manuscript only, and no clinical or outcome data are included or discussed. The reviewer may have misunderstood this context. Reviewer: 4 I have a few comments / requests for clarification / justification. Methods: 1. Please give greater detail regarding blinding. You state that investigators involved in the OFC will be blinded to CoMiSS results. What about the other way round? Will all CoMiSS assessments be made blind and also by whom? You mention that 'investigators' will perform the assessments (OFC and CoMiSS) but it is not clear who they are, and importantly whether they are blinded, or even the same person (and completely unblinded) The study will be conducted single-blinded with regard to the OFC and CoMiSS assessments. These will be done by independently study doctors, i.e. the OFC doctor will be blinded to the CoMiSS results, and vice versa. The interventions of are open-label, i.e. first amino acid-based formula, followed by OFC with cow's milk-based formula. This has been made clearer in the manuscript.
2. Please give greater detail of precisely how the OFC will be assessed and by who. How will you ensure that this 'gold standard' test will be applied correctly across all these centres by multiple investigators? What are the specific objective criteria for a positive or negative test? The OFC will be performed as per the outlined procedure. This involves a typical dose escalation of cow's milk-based formula while observing for clinical symptoms. The OFC will be performed in hospital on Day 1 and continued at home for a full week, as tolerated. The challenge will be supervised by a study doctor who has been trained in the challenge procedure (standardized training procedure, including training video in Chinese language). Positive symptoms include immediate symptoms (vomiting, hives, facial angioedema, wheeze, stridor) and delayed-onset symptoms (vomiting, increased regurgitation, persistent diarrhoea, increased eczema, irritability/pers istent crying). The doctor supervising the OFC is blinded to the CoMiSS scores. These details have been added to the manuscript. 3. Please provide some justification for gestational age and birthweight inclusion/exclusion criteria Please see above comments.
Oversight. Who is the sponsor? What are the financial arrangements? Not just overall but in terms of payments to sites etc What is the trial status and relevant start/end dates? There is no mention of a trial steering committee -please clarify. .
The study is sponsored by Nestlé Health Science, Switzerland. Funding included site funding for study setup and running, as well reimbursement of travel expenses and provision of study formula to participants. The Contract Research Organisation (CRO) is George Clinical, Sydney, Australia, who are overseeing conduct of the study, including adverse event and data entry monitoring. The independent data management and statistics company is Cytel, Cambridge MA, USA. The study started recruitment in January 2018, and completion of data collection and analysis is expected by June 2018. A dedicated paragraph with these details has been added Minor comments -there are a couple of typos on page 11 line 34 (extra of) and line 43 (OCF); page 15 line 55 (extra will) These have been amended.
Reviewer: 5 While the study is well structured, I have some comments listed below: 1. According to BMJ guidelines the dates of the study must be included in the manuscript. This has been added.
2. Patients should be consecutively included with no regard to the severity of the disease in order to avoid a biased study. The study should enroll prospectively all consecutive eligible patients with suspected disease. For example studies that make inappropriate exclusions, (excluding "difficult to diagnose" patients), may result in overoptimistic estimates of diagnostic accuracy. Therefore study subjects recruitment methods should be better specified. Patients will be consecutively enrolled according to the inclusion and exclusion criteria, without any regard to severity of CMPA symptoms. This has been added.
3. The ability of the index test to indicate which individuals have milk allergy and which do not can change with the prevalence of disease. For this reason it is important to know the population for which CoMISS is intended to be used (general or tertiary center population). In line 37 page 5 you write that the primary goal is the development of a diagnostic tool for CMPA intended for use in the primary care setting and in line 18 page 9 you write that the recruitment of the study subjects will take place in 10 pediatric departments; further information on level of care setting is required. We acknowledge this as a possible limitation. There may be differences in prevalence of CMPA between the study sites in China and future clinical setting. However, this is to some extent unavoidable. The study design will not allow to provide a population-based prevalence estimate but will provide the frequency of challenge-proven CMPA in the study cohort. 4. The OFC results will be interpreted without knowledge of the results of the CoMISS (line 12 page 8) however the interpretation of index test results may be influenced at the third visit by knowledge of the OFC results. It would be better if both investigators are blinded. Investigators conducting the OFC and the final CoMiSS will remain blinded to each of the results. Please also refer to previous comments.
5. In the "study objectives" section you write that the main aim of the trial is to validate the CoMiSS against the diagnostic reference standard, the OFC. In the introduction of abstract and in other sections (line 14 page 5, line 38 page 12), you also write that the aim of the study is to validate the CoMiSS as a potential diagnostic tool for CMPA and as a predictor of CMPA. I think you run the risk of failing to answer the main aim it set out to achieve. We are of the opinion that validation against and open OFC in conjunction with the response to amino acid-based formula, represents an acceptable clinical validation as the diagnostic standard of CMPA (refer ESPGHAN guidelines / ref #3). We acknowledge that this is a pragmatic decision that may be viewed as a study limitation, as compared to the more rigorous DBPCFC.
Your purpose is actually to propose the CoMISS as a diagnostic test for milk allergy and not as a screening test. CoMISS cut-off should minimize false positives because the purpose of CoMISS is to avoid OFC for those patients suspected to be allergic and to avoid useless elimination diets. In line 7 page 13 you write "a meaningful CoMiSS cut-off can be identified that would provide a high sensitivity (around 80%-90%) and moderate specificity in the range of 60%-70%" however for the mentioned reasons you should identify CoMiss cut-off that would provide a high specificity. We have deliberately aimed for a high sensitivity of at least 80% in order to reduce the risk of false-negative results in the primary care setting. However, we agree with the reviewer that a high specificity for a diagnosis of CMPA would also be desirable. Modelling of various CoMiSS cut -offs will be undertaken using the training dataset to identify an optimum set of sensitivity and specificity as part of the ROC analysis.
6. The determination of CoMISS optimal cut-off is among the secondary objectiveness. Cut-off based on the best combination between sensibility and specificity does not allow to adequately select patients at high risk of reacting to the OFC. Furthermore sensibility and s pecificity are a fixed characteristic of the test. In order to obtain most clinically useful measures, I suggest you to provide Likelihood Ratio (LR). LR is one of the most clinically useful measures, more useful than sensitivity or specificity and summarize information about a diagnostic test by combining sensitivity and specificity.
We agree with the reviewer and have added likelihood ratios to the analysis plan. Please also refer to the above comments.
7. In abstract section you indicate that the study will calculated the difference between CoMiSS 1 and 2 but this aim is not listed in the outcomes section.
We thank the reviewer for this valuable comment. This has been added to the analysis plan. 8. Enrolment is indicated in figure 2 at visit 1 while you write in the manuscript that infants will be considered for inclusion at visit 2 (line 28 and 47 page 24).
Patients will be enrolled at visit 1, not at the screening visit. This has been clarified in the text and amended in Figure 2 .
VERSION 2 -REVIEW
REVIEWER
Stephanie Leonard Stanford University School of Medicine, USA REVIEW RETURNED 10-Jan-2018
GENERAL COMMENTS
Second bullet under Strengths and Limitations is a study aim, not a study strength. The study is well structured, it adequately meets to the four key domains of QuaDA-2:the study provide information about the method of recruitment of patients (based on prospective and consecutive series of patients with suspcted symptoms) and it doesn't make inappropriate exclusions; all enrolled patients shall be tested without exclusion; investigators are blinded and interpretation of CoMiss results cannot be influenced by knowledge of the reference standard OFC and finaly there is an appropriate interval between assessment of CoMiss and OFC.
REVIEWER
The sample size has been calculated and all recruited patients will be included in the analysis.
However it is not yet clear if CoMiss test is proposed as an alternative diagnostic test for milk allergy or not.
Specific tests are typically used to confirm a suspected diagnosis while sensitivity test are used as a screening test to select a population of candidate patients (the patients may be suspected of having a milk allergy) for TPO. You aim to assess a cut-off value with high sensitivity and low specificity. Sensitivity is the test's ability to correctly designate a subject with the disease as pos itive; tests with high sensitivity have potential value for screening, because they rarely miss subjects with the disease. Thus I understand that a major objective of CoMiss test is to reduce the need for food challenges and not to replace it. If that is the case the concept needs to be clarified in line 20 page 2 and in line 31 pag 9 and in the title.
On the contrary, if you want a diagnostic cut off, choose an high specific value.
VERSION 2 -AUTHOR RESPONSE
Editorial Requests:
The quality of English still needs improving in places. Please thoroughly proofread the paper before submitting your revision.
The paper was proofread (again) by two coauthors. RM is a USA citizen, and RGH lived for many years in Australia and was the language proofreader of the team. Some typo's were found and corrected.
Protocol for the validation of the Cow's Milkrelated Symptom Score (CoMiSSTM 1) against response to amino acid-based formula and open food challenge in a single-blinded, prospective, multi-centre trial." The title also does not currently include the study population (as requested in the SPIRIT checklist).
The title has been amended : Protocol for validation of the sensitivity of the Cow's Milkrelated Symptom Score (CoMiSS TM ) in infants against response to amino acid-based formula and open food challenge in a single-blinded, prospective, multi-centre trial Why is the 2nd bullet point of the 'strengths and limitations' section a strength relating to the design or methods of the study? It appears to be your study's aim.
This bullet point was deleted
Can you elaborate on how adverse events will be collected, assessed, reported, and managed (as requested in SPIRIT checklist item 22)?
We added the following to the manuscript: Adverse events will be reported in the patient file. They will be assessed and managed according to good clinical practice. Adverse events are part of the secondary outcomes and will be listed in the final study report.
Reviewer: 2
Second bullet under Strengths and Limitations is a study aim, not a study strength.
This bullet point was deleted
Reviewer: 5
We thank the reviewer for the nice suggestions and comments However it is not yet clear if CoMiss test is proposed as an alternative diagnostic test for milk allergy or not.
Specific tests are typically used to confirm a suspected diagnosis while sensitivity test are used as a screening test to select a population of candidate patients (the patients may be suspected of having a milk allergy) for TPO. You aim to assess a cut-off value with high sensitivity and low specificity. Sensitivity is the test's ability to correctly designate a subject with the disease as positive; tests with high sensitivity have potential value for screening, because they rarely miss subjects with the disease. Thus I understand that a major objective of CoMiss test is to reduce the need for food challenges and not to replace it. If that is the case the concept needs to be clarified in line 20 page 2 and in line 31 pag 9 and in the title.
We rephrased: Based on this threshold, we aim to identify a meaningful CoMiSS cut-off that would provide a high sensitivity (around 80%-90%) in order to pick-up all infants suspected of CMPA and minimise the number of infants that have a CoMiSS below the proposed threshold and would have a positive OFC, and moderate specificity in the range of 60%-70% for predicting a positive OFC (i.e. diagnosis of CMPA).
